Literature DB >> 12470419

A model for evaluating selective delivery of plasmid DNA to tumours via the vasculature.

Crispin R Dass1, Mark A Burton.   

Abstract

A comparative study of plasmid DNA delivery in a newly established rat renal solid tumour model was undertaken. Free plasmid, plasmids bound to microspheres, and plasmids complexed with liposomes were selectively delivered to tumours via arterial catheterisation. Forty-eight hours post delivery, tumour to normal kidney tissue chloramphenicol acetyltransferase expression ratios were as follows: free (1.8:1), microspherical (3.9:1), and liposomal (1.2:1). Microspheres were able to selectively deliver the plasmids to tumours, whereas cationic liposomes distributed the plasmids to both kidney parenchymal and tumour cells. This tumour model has the potential of screening delivery vehicles as well as therapeutic agents for the capacity of selective delivery to tumours via the vasculature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470419     DOI: 10.1089/108497802760804727

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  4 in total

Review 1.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

2.  An in vitro release study of 5-fluoro-uracil (5-FU) from swellable poly-(2-hydroxyethyl methacrylate) (PHEMA) nanoparticles.

Authors:  Raje Chouhan; A K Bajpai
Journal:  J Mater Sci Mater Med       Date:  2009-01-10       Impact factor: 3.896

3.  Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy.

Authors:  Crispin R Dass; Peter F M Choong
Journal:  Cancer Cell Int       Date:  2006-06-23       Impact factor: 5.722

Review 4.  Barriers to Liposomal Gene Delivery: from Application Site to the Target.

Authors:  Mostafa Saffari; Hamid Reza Moghimi; Crispin R Dass
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.